Merck EVP DeLuca sells 37,685 MRK shares

Merck & Co., Inc. executive Richard R. DeLuca, Jr. reported a sale of company stock.

Accepted by SEC EDGAR 02/06/2026 - 04:08 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Merck & Co., Inc. executive Richard R. DeLuca, Jr. reported a sale of company stock. On 02/06/2026, he sold 37,685 shares of Merck common stock at a weighted average price of $120.9241 per share, in multiple trades between $120.7350 and $121.3054.

After this transaction, DeLuca directly beneficially owned 160,173.834 Merck shares. The filing lists him as Executive Vice President and President, Merck Animal Health, and shows no derivative securities activity for this date.

Insider Trade Summary

Net Seller: 37,685 shares

Net Sell 1 txn

Insider DeLuca Richard R.

Role EVP&Pres, Merck Animal Heallth

Sold 37,685 shs ($4.56M)

Share of Position Sold 19.0%

Type	Security	Shares	Price	Value
Sale	Common Stock	37,685	$120.9241	$4.56M

Holdings After Transaction: Common Stock — 160,173.834 shares (Direct)

Holdings Before and After: Common Stock, 197,858.834 to 160,173.834 shares (Direct)

Other Insiders: 7 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.7350 to $121.3054, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Merck (MRK) executive Richard R. DeLuca, Jr. report in this Form 4?

Richard R. DeLuca, Jr., EVP and President of Merck Animal Health, reported selling 37,685 shares of Merck common stock. The transaction occurred on 02/06/2026 and is classified as a non-derivative sale under transaction code "S" in the insider filing.

At what price did Richard R. DeLuca, Jr. sell Merck (MRK) shares?

The reported sale used a weighted average price of $120.9241 per share. Shares were sold in multiple trades at prices ranging from $120.7350 to $121.3054, as detailed in the footnote explaining the weighted average calculation for the reported transaction.

How many Merck (MRK) shares does Richard R. DeLuca, Jr. own after this transaction?

Following the reported sale, Richard R. DeLuca, Jr. beneficially owned 160,173.834 shares of Merck common stock directly. This post-transaction holding reflects his remaining direct ownership after disposing of 37,685 shares on 02/06/2026 in the reported Form 4 filing.

What role does Richard R. DeLuca, Jr. hold at Merck (MRK) in this filing?

The filing identifies Richard R. DeLuca, Jr. as an officer of Merck & Co., Inc., with the title "EVP&Pres, Merck Animal Heallth." This indicates he serves as Executive Vice President and President of Merck Animal Health at the time of the reported stock transaction.

Does this Merck (MRK) Form 4 involve any derivative securities transactions?

The Form 4 includes a section for derivative securities but shows no reported derivative transactions for this date. Only a non-derivative common stock sale of 37,685 shares is disclosed, with details on price, transaction code, and post-transaction share ownership.

How is the sale price range for Richard R. DeLuca, Jr.’s Merck (MRK) shares described?

The footnote states the reported price is a weighted average of multiple trades. Shares were sold at prices between $120.7350 and $121.3054, inclusive, and the reporting person offers to provide detailed breakdowns of shares sold at each individual price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLuca Richard R.

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP&Pres, Merck Animal Heallth

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		S		37,685	D	$120.9241(1)	160,173.834	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.7350 to $121.3054, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.